Skip to main content

Topical Halobetasol Propionate in the Treatment of Plaque Psoriasis

A Review

American Journal of Clinical Dermatology volume 6, pages 311–316 (2005)Cite this article

Abstract

Halobetasol propionate (HP) 0.5% ointment and cream are class I topical corticosteroids. We review the efficacy and tolerability of HP for treatment of plaque psoriasis in the English language literature. The efficacy of HP ointment and cream is consistently superior to other super-potent topical corticosteroids. Local adverse events associated with topical HP are similar to those experienced with other super-potent corticosteroids. Combination therapy with calcipotriene (calcipotriol) and tazarotene appears to be superior to monotherapy with topical HP.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 49.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Table I
Table II
Table III

References

  1. Green MS, Prystowsky JH, Cohen SR, et al. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol 1996; 34: 911–4

    PubMed  Article  CAS  Google Scholar 

  2. Lebwohl M. Psoriasis. Lancet. 2003; 361: 1197–204

    PubMed  Article  Google Scholar 

  3. Stern RS. Epidemiology of psoriasis. Dermatol Clin. 1995; 13: 717–22

    PubMed  CAS  Google Scholar 

  4. Witman PM. Topical therapies for localized psoriasis. Mayo Clin Proc. 2001; 76: 943–9

    PubMed  CAS  Google Scholar 

  5. Federman DG, Froelich CW, Kirsner RS. Topical psoriasis therapy. Am Fam Physician. 1999; 59: 957–962, 964

    PubMed  CAS  Google Scholar 

  6. Yawalkar S, Wiesenberg-Boettcher I, Gibson JR, et al. Dermatopharmacologic investigations of halobetasol propionate in comparison with clobetasol 17-propionate. J Am Acad Dermatol. 1991; 25: 1137–44

    PubMed  Article  CAS  Google Scholar 

  7. Bernhard J, Whitmore C, Guzzo C, et al. Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studies. J Am Acad Dermatol. 1991; 25: 1170–4

    PubMed  Article  CAS  Google Scholar 

  8. Katz HI, Gross E, Buxman M, et al. A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis. J Am Acad Dermatol. 1991; 25: 1175–8

    PubMed  Article  CAS  Google Scholar 

  9. Blum G, Yawalkar S. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis. J Am Acad Dermatol. 1991; 25: 1153–6

    PubMed  Article  CAS  Google Scholar 

  10. Goldberg B, Hartdegen R, Presbury D, et al. A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. J Am Acad Dermatol. 1991; 25: 1145–8

    PubMed  Article  CAS  Google Scholar 

  11. Mensing H, Korsukewitz G, Yawalkar S. A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis. J Am Acad Dermatol. 1991; 25: 1149–52

    PubMed  Article  CAS  Google Scholar 

  12. Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized psoriasis and atopic dermatitis. J Am Acad Dermatol. 1991; 25: 1166–9

    PubMed  Article  CAS  Google Scholar 

  13. Katz HE Prawer SE, Medansky RS, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica. 1991; 183: 269–74

    PubMed  Article  CAS  Google Scholar 

  14. Brunner N, Yawalkar S. A double-blind, multicenter, parallel-group trial with 0.05% halobetasol propionate ointment versus 0.1% diflucortolone valerate ointment in patients with severe, chronic atopic dermatitis or lichen simplex chronicus. J Am Acad Dermatol. 1991; 25: 1160–3

    PubMed  Article  CAS  Google Scholar 

  15. Datz B, Yawalkar S. A double-blind, multicenter trial of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicus. J Am Acad Dermatol. 1991; 25: 1157–60

    PubMed  Article  CAS  Google Scholar 

  16. Kantor I, Cook PR, Cullen SI, et al. Double-blind bilateral paired comparison of 0.05% halobetasol propionate cream and its vehicle in patients with chronic atopic dermatitis and other eczematous dermatoses. J Am Acad Dermatol. 1991; 25: 1184–6

    PubMed  Article  CAS  Google Scholar 

  17. Yawalkar SJ, Schwerzmann L. Double-blind, comparative clinical trials with halobetasol propionate cream in patients with atopic dermatitis. J Am Acad Dermatol. 1991; 25: 1163–6

    PubMed  Article  CAS  Google Scholar 

  18. Watson WA, Kalb RE, Siskin SB, et al. The safety of halobetasol 0.05% ointment in the treatment of psoriasis. Pharmacotherapy. 1990; 10: 107–11

    PubMed  CAS  Google Scholar 

  19. Walsh P, Aeling JL, Huff L, et al. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol. 1993; 29: 501–3

    PubMed  Article  CAS  Google Scholar 

  20. Katz HI, Hien NT, Prawer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris: clinical efficacy and adrenal function. J Am Acad Dermatol. 1987; 16: 804–11

    PubMed  Article  CAS  Google Scholar 

  21. Lebwohl M, Yoles A, Lombardi K, et al. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol. 1998; 39: 447–50

    PubMed  Article  CAS  Google Scholar 

  22. Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol. 1996; 35: 268–9

    PubMed  Article  CAS  Google Scholar 

  23. Lebwohl M. Topical application of calcipotriene and corticosteroids: combination regimens. J Am Acad Dermatol. 1997; 37: S55–8

    PubMed  Article  CAS  Google Scholar 

  24. Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment: a review of its use in the management of psoriasis. Am J Clin Dermatol. 2001; 2 (2): 95–120

    PubMed  Article  CAS  Google Scholar 

  25. Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003; 48: 48–54

    PubMed  Article  Google Scholar 

  26. Guenther L, Van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002; 147: 316–23

    PubMed  Article  CAS  Google Scholar 

  27. Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol. 1998; 139: 649–54

    PubMed  Article  CAS  Google Scholar 

  28. Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med. 1999; 107: 595–605

    PubMed  Article  CAS  Google Scholar 

  29. Green L, Sadoff W. A clinical evaluation of tazarotene 0.1% gel, with and without a high-or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg. 2002; 6: 95–102

    PubMed  Article  Google Scholar 

  30. Hecker D, Worsley J, Yueh G, et al. In vitro compatibility of tazarotene with other topical treatments of psoriasis. J Am Acad Dermatol. 2000; 42: 1008–11

    PubMed  Article  CAS  Google Scholar 

  31. Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998; 39: 590–6

    PubMed  Article  CAS  Google Scholar 

  32. Lebwohl M, Poulin Y. Tazarotene in combination with topical corticosteroids. J Am Acad Dermatol. 1998; 39: S139–43

    PubMed  Article  CAS  Google Scholar 

  33. Gollnick H, Menter A. Combination therapy with tazarotene plus a topical cortico-steroid for the treatment of plaque psoriasis. Br J Dermato. 1999; 140 Suppl. 54: 18–23

    Article  CAS  Google Scholar 

  34. Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther. 2000; 22: 1225–38

    PubMed  Article  CAS  Google Scholar 

  35. Tanghetti EA. An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid. Cutis. 2000; 66: 4–11

    PubMed  CAS  Google Scholar 

  36. Lebwohl M. Psoriasis. In: Lebwohl MG, Heymann W, Berth-Jones J, et al., editors. Treatment of Skin Disease: Comprehensive Treatment Strategies. New York: Mosby International, 2002: 533–43

    Google Scholar 

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Department of Dermatology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas, TX 77030, USA

    Allison M. Rivera &  Sylvia Hsu

Authors
  1. Allison M. Rivera
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sylvia Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sylvia Hsu.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rivera, A.M., Hsu, S. Topical Halobetasol Propionate in the Treatment of Plaque Psoriasis. Am J Clin Dermatol 6, 311–316 (2005). https://doi.org/10.2165/00128071-200506050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200506050-00004

Keywords

  • Psoriasis
  • Topical Corticosteroid
  • Plaque Psoriasis
  • Calcipotriol
  • Tazarotene